Methylene Blue and Breastfeeding: What the Evidence Actually Shows

Methylene blue is an old synthetic dye with a surprisingly broad pharmacological profile, attracting growing attention in longevity and brain health circles for its potential mitochondrial and cognitive benefits. Understanding its behavior in human physiology — including during breastfeeding — is increasingly relevant as its use expands beyond traditional clinical indications like methemoglobinemia.

This LactMed database entry reviews the available evidence on methylene blue's passage into human breastmilk. The central question is whether nursing mothers who receive methylene blue expose their infants to meaningful drug concentrations through milk.

The key finding from older research is that breastmilk was not visibly discolored following maternal administration of methylene blue — a notable observation, given that the compound is intensely blue in solution. This suggests limited transfer into milk, which is pharmacologically plausible: methylene blue is approximately 94% protein-bound, and highly protein-bound drugs generally penetrate milk poorly.

Despite this, current prescribing labels recommend discontinuing breastfeeding during administration and for up to 8 days afterward. This conservative guidance appears to derive from the drug's half-life of approximately 24 hours — roughly 5 half-lives would clear most of the drug within that window — rather than from demonstrated infant harm or confirmed milk levels.

The practical implication is that current safety guidance is precautionary by design, not evidence-based in the conventional sense. No studies have measured actual methylene blue concentrations in breastmilk, and no data exist on the safety of oral methylene blue specifically during lactation. For clinicians and patients navigating this question, the absence of evidence is not evidence of absence, and the conservative label recommendation likely reflects appropriate caution under uncertainty.